Roche’s senior VP of global oncology product strategy, Cindy Perettie, is jumping over to become the next CEO of Foundation Medicine, which the Big Pharma acquired last year through a $2.4 billion buyout.
Perettie will succeed Troy Cox, effective Feb. 4, to take the reins for what Cox describes as the next phase of growth for the genomic diagnostic developer and Fierce 15 company.
“As we look ahead, the advancements across our molecular information portfolio position the company to continue to lead in precision oncology and Cindy is well poised to accelerate our work to bring these advances forward and transform cancer care for patients,” Cox said in a statement.
“My time at Foundation Medicine has been one of the most rewarding of my career. The mission, the people, and the impressive progress we have made together has been life-changing for me. I am grateful to carry that with me into my next chapter,” he added.
RELATED: Roche inks $2.4B deal to buy out Foundation Medicine
Perettie has helped lead several oncology product launches for both Roche and Genentech, including in breast cancer and hematology. She began at Genentech in 2004 as a program team leader for Avastin, focused on lung cancer, breast cancer, gastrouterine cancer and melanoma. Since then, she’s served as VP of global regulatory operations and regional head of Europe, Middle East and Africa operations.
RELATED: FierceBiotech’s 2012 Fierce 15 | Foundation Medicine
Perettie also took a hiatus from Genentech in 2012, joining the Sarah Cannon Research Institute as president of global development innovations, where she helped lead its cancer-focused contract research organization business.